KRAS Mutation and Primary Tumor Location Do Not Affect Efficacy of Bevacizumab-Containing Chemotherapy in Stagae IV Colorectal Cancer Patients
Open accessAbstract
This study aims to investigate the efficacy of bevacizumab-combined chemotherapy (BCC) in Chinese stage IV colorectal cancer (CRC), and analyze the relationship between clinicopathological features with survival. Patients with stage IV CRC treated with BCC were analyzed retrospectively. 217 metastatic CRC (mCRC) patients were collected, out of which79 were right-sided CRCs and 138 were left-sided ones. Patients with Eastern Cooperative Oncology Group (ECOG) performance status ≤2, single agent chemotherapy, poor/mucous/signet ring cell component, second-and further-line of bevacizumab administration, multiple metastasis sites had comparatively worse survival. Among 141 patients with known KRAS status, 55 patients harbored KRAS mutation and 86 had wild type KRAS. The ORR and DCR were 41.9% and 78.9%, respectively, in patients with wild type KRAS, while ORR and DCR was 38.7% and 77.9%, respectively, in patients with KRAS mutation. The median PFS of patients with wild type and mutant KRAS were 8.38, and9.59 months, respectively; whereas the OS was 23.00 and 21.26 months, respectively for mCRC patients with wild-type and mutant KRAS. Cumulatively, our study indicated that BCC was effective and beneficial for Chinese stage IV CRC patients. KRAS mutation status and tumor location were not a prognostic factor for survival.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In colorectal cancers, chemotherapy in combination with anti-VEGF antibody is similarly effective in KRAS-mutant and wild-type tumors.
“In case of colorectal cancers, chemotherapy in combination with anti-VEGF antibody is similarly effective in KRAS-mutant and wild-type tumors [69].”
From Hypoxia Signaling in Cancer: From Basics to Clinical Practice (2021) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854 · see citing works
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · see citing works
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955 · see citing works
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279 · see citing works
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184 · see citing works
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · see citing works
Bennouna, J., Sastre, J., Arnold, D., Österlund, P., Greil, R., Van Cutsem, E., von Moos, R., Viéitez, J. M., Bouché, O., Borg, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70477-1 · Cited by 1,166 · see citing works
Are there two sides to colorectal cancer?
Iacopetta, B. J. (2002) · International Journal of Cancer · doi:10.1002/ijc.10635 · Cited by 781 · see citing works
Benedix, F., Kube, R., Meyer, F. P., Schmidt, U., Gastinger, I., & Lippert, H. (2010) · Diseases of the Colon & Rectum · doi:10.1007/dcr.0b013e3181c703a4 · Cited by 714 · see citing works
Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features
Missiaglia, E., Jacobs, B., D’Ario, G., Narzo, A. F. D., Soneson, C., Budínská, E., Popovici, V. C., Vecchione, L., Gerster, S., Yan, P., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu275 · Cited by 646 · see citing works
Is There a Difference in Survival between Right- versus Left-Sided Colon Cancers?
Meguid, R. A., Slidell, M. B., Wolfgang, C. L., Chang, D. C., & Ahuja, N. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0015-y · Cited by 546 · see citing works
Cutsem, E. V., Rivera, F., Berry, S. R., Kretzschmar, A., Michael, M., Bartolomeo, M. D., Mazier, M., Canon, J.-L., Georgoulias, V., Peeters, M., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp233 · Cited by 531 · see citing works
Simkens, L. H. J., van Tinteren, H., May, A. M., ten Tije, A. J., Creemers, G., Loosveld, O. J. L., de Jongh, F. E., Erdkamp, F., Erjavec, Z., van der Torren, A. M. E., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62004-3 · Cited by 522 · see citing works
Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer
Loupakis, F., Yang, D., Yau, L., Feng, S., Cremolini, C., Zhang, W., Maus, M. K. H., Antoniotti, C., Langer, C., Scherer, S. J., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju427 · Cited by 477 · see citing works
Ciardiello, F., Bianco, R., Damiano, V., Fontanini, G., Caputo, R., Pomatico, G., Placido, S. D., Bianco, A. R., Mendelsohn, J. M., & Tortora, G. (2000) · PubMed · Cited by 379 · see citing works
Kozloff, M. F., Yood, M. U., Berlin, J. D., Flynn, P. J., Kabbinavar, F. F., Purdie, D. M., Ashby, M. A., Dong, W., Sugrue, M. M., Grothey, A. F., et al. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0071 · Cited by 305 · see citing works
Sinicrope, F. A., Mahoney, M. R., Smyrk, T. C., Thibodeau, S. N., Warren, R. S., Bertagnolli, M. M., Nelson, G. D., Goldberg, R. M., Sargent, D. J., & Alberts, S. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.9591 · Cited by 280 · see citing works
Hurwitz, H. I., Yi, J., Ince, W., Novotny, W. F., & Rosen, O. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0213 · Cited by 239 · see citing works
Díaz‐Rubio, E., Gómez‐España, A., Massutí, B., Sastre, J., Abad, A., Valladares, M., Rivera, F., Safont, M. J., de Prado, P. M., Gallén, M., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0249 · Cited by 210 · see citing works
Masi, G., Salvatore, L., Boni, L., Loupakis, F., Cremolini, C., Fornaro, L., Schirripa, M., Cupini, S., Barbara, C., Safina, V., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv012 · Cited by 175 · see citing works
Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer
Krämer, I., & Lipp, H. (2007) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2007.00800.x · Cited by 123 · see citing works
Guan, Z.-Z., Xu, J.-M., Luo, R.-C., Feng, F.-Y., Wang, L.-W., Shen, L., Yu, S., Ba, Y., Liang, J., Wang, D., et al. (2011) · 癌症：英文版 · doi:10.5732/cjc.011.10188 · Cited by 114 · see citing works
Role of bevacizumab in colorectal cancer growth and its adverse effects: A review
Pavlidis, T. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i31.5051 · Cited by 106 · see citing works
Bendell, J. C., Bekaii‐Saab, T., Cohn, A. L., Hurwitz, H. I., Kozloff, M., Tezcan, H., Roach, N., Mun, Y., Fish, S. M., Flick, E. D., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0190 · Cited by 101 · see citing works
Bleeker, W. A., Hayes, V. M., Karrenbeld, A., et al. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.02327.x · Cited by 71 · see citing works
Clinical Medicine Insights: Oncology
(2016) · Clinical Medicine Insights Oncology · doi:10.4137/cmo · Cited by 60 · see citing works
Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer
Wong, H., Lee, B., Field, K. M., et al. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.02.007 · Cited by 53 · see citing works
Vascular endothelial growth factor (VEGF) - part 2: in endocrinology and oncology.
Kajdaniuk, D., Marek, B., Fołtyn, W., & Kos‐Kudła, B. (2011) · PubMed · Cited by 48 · see citing works
Sunakawa, Y., Ichikawa, W., Tsuji, A., Denda, T., Segawa, Y., Negoro, Y., Shimada, K., Kochi, M., Nakamura, M., Kotaka, M., et al. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.09.010 · Cited by 44 · see citing works
Karzinome des rechten und linken Kolons – verschiedene Tumorentitäten?
Benedix, F., Meyer, F., Kube, R., et al. (2010) · Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie · doi:10.1055/s-0030-1247471 · Cited by 34 · see citing works
Cidón, E. U., Alonso, P., & Masters, B. (2016) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s34542 · Cited by 28 · see citing works
A Tale of Two Colons and Two Cancers
Gervaz, Bühler, Scheiwiller, et al. (2003) · Swiss Surgery · doi:10.1024/1023-9332.9.1.3 · Cited by 9 · see citing works
Dai, Wu, Shi, Y. X., Chen, C., & Xiao, X. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s41449 · Cited by 6 · see citing works
Self-citationCabart, M., Frenel, J., Campion, L., Ramée, J., Dupuis, O., Senellart, H., Hiret, S., Douillard, J., & Bennouna, J. (2016) · Bulletin du Cancer · doi:10.1016/j.bulcan.2016.03.007 · Cited by 5 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Hypoxia Signaling in Cancer: From Basics to Clinical Practice
Sebestyén, A., Kopper, L., Dankó, T., & Tímár, J. (2021) · Pathology and Oncology Research · doi:10.3389/pore.2021.1609802 · Cited by 110 · see citing works
- Authors
- Sun, D.-C., Shi, Y., Wang, Y.-R., Lv, Y., Yan, H., Mao, H., Wang, Z.-K., Wu, Z.-Y., Shi, W.-W., & Dai, G.-H.
- Affiliations
- Chinese PLA General Hospital (CN)
- Venue
- Scientific Reports
- Published
- 2017-10-30
- Volume
- 7
- Issue
- 1
- Pages
- 14368-14368
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC5662591
- OpenAlex
- W2765952344
- Cited by
- 16
- References
- 35
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 2 · 2020: 5 · 2019: 2 · 2018: 1 · 2017: 1
- FWCI
- 1.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- General Hospital of People’s Liberation Army
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Keywords
- KRAS mutation, primary tumor site, bevacizumab, metastatic colorectal cancer, stage IV colorectal cancer, prognostic factors, overall survival, progression-free survival, Chinese patients
- MeSH terms
- Bevacizumab, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, China, Colonic Neoplasms, Female, Humans, Male, Middle Aged, Mutation, Prognosis, Rectal Neoplasms, Retrospective Studies, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Treatment Outcome, ras Proteins, Asian People, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
